De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects

Transplantation

Volumn 83, Issue 9, 2007, Pages 1162-1168

  Toso, Christian ^a   Meeberg, Glenda A ^a   Bigam, David L ^a   Oberholzer, Jose ^b   Shapiro, A M James ^a   Gutfreund, Klaus ^a   Ma, Mang M ^a   Mason, Andrew L ^a   Wong, Winnie W S ^a   Bain, Vincent G ^a   Kneteman, Norman M ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c 2D441 Walter Mackenzie Center ^*  (Canada)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Sirolimus

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CEFOTAXIME; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; DACLIZUMAB; ERYTHROPOIETIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN; IRON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; RAPAMYCIN; STEROID; TACROLIMUS;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; AGED; ANEMIA; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCISIONAL HERNIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH ULCER; MYCOSIS; PERITONITIS; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PILOT PROJECTS; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34248327483     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000262607.95372.e0     Document Type: Article

References (32)

1. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with Target-of-Rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Am J Transplant 2005; 80: 883.
2. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984; 37: 1231.
3. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
4. Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105: 4463.
5. Schumacher G, Oidtmann M, Rueggeberg A, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 14: 1420.
6. Kneteman N, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
7. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701.
8. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticoids (3-day taper). Liver Transpl 2001; 7: 343.
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
10. Yao F, Ferrell L, Bass N, et al. Liver transplantation for hepatocellular carcinomas: Expension of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
11. Sobin L, Wittekind C. TNM classification of malignant tumours. New York: Wiley-Liss, 2002: 81.
12. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777.
13. Yao F, Ferrell L, Bass N, et al. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburg modified TNM criteria. Liver Transpl 2002; 8: 765.
14. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transpl 2005; 11: 497.
15. Zavaglia C, de Carlis L, Alberti B, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708.
16. Leung J, Zhu A, Gordon F, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: Results of a multicenter study. Liver Transplant 2004; 10: 1343.
17. Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: Predictive value of nodule size in a retrospective and explant study. Transplantation 2006; 81: 1532.
18. Roayaie S, Schwartz J, Sung M, et al. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and Prognosis. Liver Transpl 2004; 10: 534.
19. Gondolesi G, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma. Extending UNOS priority criteria. Ann Surg 2004; 239: 142.
20. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2005; 239: 150.
21. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of posttransplant lung metastasis from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855.
22. Ciancio G, Burke G, Gaynor J, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 years. Transplantation 2004; 77: 252.
23. Mendez R, Gonwa T, Yang H, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303.
24. Larson T, Dean P, Stegall M, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
25. Trotter JF, Wachs M, Trouillot T, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 401.
26. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-raletd complications. Transplantation 2004; 78: 264.
27. Samonakis D, Cholongitas E, Triantos C, et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091.
28. Cameron A, Ghobrial R, Hiatt J, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006; 244: 563.
29. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463.
30. Kandaswamy R, Melancon J, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-An interim analysis. Am J Transplant 2005; 5: 1529.
31. Ceydeli A, Rucinski J, Wise L. Finding the best abdominal closure: An evidence-based review of literature. Curr Surg 2005; 62: 220.
32. Janssen H, Lange R, Erhard J, et al. Causative factors, surgical treatment and outcome of incisional hernia after liver transplantation. Br J Surg 2002; 89: 1049.